Today before the opening bell,
International Stem Cell Corp., a biotechnology company developing novel stem
cell based therapies and biomedical products, announced publication of results
of two proof-of-concept studies that validate the safety and efficacy of the
company’s readily expandable stem cell derived treatment of Parkinson’s disease
in both non-human primate and rodent animal models.
“The publication of these data in the
peer-reviewed and highly-respected journal, Cell Transplantation, brings to a
conclusion the preclinical stage of our Parkinson’s disease program. The data
clearly support the premise that parthenogenetic neural stem cells can be
effective in treating the symptoms of Parkinson’s disease and, along with the
previously reported safety data, forms the basis of our decision to move into the
clinic,” stated Ruslan Semechkin, Ph.D., the Company’s Chief Scientific
Officer. “We look forward to providing an update on the status of our
regulatory submission to the Australian government in the near future.”
In addition to successfully treating animals
with induced Parkinson’s disease symptoms by transplanting human
parthenogenetic neural stem cells (hpNSC), the company observed there were no
deformations, tumors or involuntary muscle movements (dyskinesia). The studies
further show that transplants of human parthenogenetic neural stem cells led to
improvement of dopamine levels and increased cytokine levels.
The article and abstract can be found
at:
http://www.ingentaconnect.com/content/cog/ct/2015/00000024/00000004/art00010
ISCO has built a comprehensive
preclinical safety dataset from a series of GLP and non-GLP studies on hpNSC.
According to today’s press release, the company has submitted a Clinical Trial
Exemption (CTX) application to the Australian regulatory authorities and plans
to begin the phase 1/2a clinical study within the next few months.
For more information on the company,
visit www.internationalstemcell.com and www.companyblog.intlstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment